Prelude Therapeutics Incorporated · NASDAQ:PRLD

OrbiMed Genesis GP LLC bought 2,815,315 Prelude Therapeutics Incorporated shares (Form 4)

Traded Apr 21, 2026 · Filed Apr 23, 2026

On Apr 21, 2026, OrbiMed Genesis GP LLC (Director, 10% owner) bought 2,815,315 Prelude Therapeutics Incorporated shares at US$4.44 for US$12.5M, leaving 1,126,126 shares. Filed Apr 23, 2026 (Form 4).

Bought
2,815,315 shares
Price
US$4.44
Value
US$12.5M
Holding after
1,126,126 shares (held indirectly)
Trading plan
No
Role
Director, 10% owner

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 21, 2026Common StockBuy1,689,189US$4.4411,808,945Indirect
Apr 21, 2026Common StockBuy1,126,126US$4.441,126,126Indirect

Source

View original at SEC

Related